Revenue distribution by industry:

• Pharmaceuticals: 100% (2025)

TOP 3 markets:

1. USA: about 95%
2. Europe: about 3%
3. Asia: about 2%

Corcept Therapeutics Incorporated generates its revenues mainly from the pharmaceutical industry, particularly through the development and marketing of drugs for the treatment of endocrine disorders. The largest market for the company is the USA, where the majority of revenues are generated. Europe and Asia follow with significantly lower shares. The strong focus on the US market is typical for many biopharmaceutical companies that generate their main revenues there.

Production Sites: USA (estimated, as of 2023)

Corcept Therapeutics Incorporated is a biopharmaceutical company that focuses on the development and commercialization of medications for the treatment of severe mental and metabolic disorders. The company primarily produces its products in the USA, relying on specialized production facilities and partner companies.

Since specific information about the exact production sites is often not detailed in public disclosures, it is assumed that Corcept centralizes its production in the USA to meet FDA regulatory requirements and optimize logistics.

Research and Development (R&D): 25% of revenue (2024)

Expansion of Indications: Focus on new therapeutic applications

Corcept Therapeutics Incorporated pursues a growth strategy that heavily relies on research and development. The company invests a significant portion of its revenue in R&D to expand its pipeline and develop new drugs.

An essential part of the strategy is expanding the indications for existing products. Corcept aims to broaden the use of its drugs to new therapeutic areas in order to increase the addressable market.

Additionally, the company plans to strengthen its presence in international markets to further promote revenue growth. This strategy is supported by partnerships and alliances with other pharmaceutical companies to accelerate the launch of new products.

Main raw materials: Active Pharmaceutical Ingredients (APIs), excipients

Countries of origin: USA, China, India

Corcept Therapeutics Incorporated is a biopharmaceutical company specializing in the development and marketing of medications. The main raw materials required by the company are Active Pharmaceutical Ingredients (APIs) and various excipients for the production of their medications.

The APIs and other chemical components are often imported from countries such as the USA, China, and India. These countries are known for their extensive production of pharmaceutical raw materials and offer competitive prices and quality.

As the pharmaceutical industry is heavily regulated, Corcept Therapeutics sources its materials from certified suppliers to ensure compliance with quality standards.

Gross Margin: 80% (2024) Research & Development (R&D) Expenses: 25% of revenue (2024)

Corcept Therapeutics Incorporated has a significant competitive advantage, primarily manifested by its high gross margin of 80%. This high margin indicates that the company is able to sell its products at a price well above the production costs, suggesting a strong market position and a differentiated product portfolio.

Another aspect of the competitive advantage is the substantial investment in research and development, accounting for 25% of revenue. These investments enable the company to continuously develop innovative therapies and strengthen its product pipeline, thereby solidifying its market position in the long term.

Additionally, Corcept Therapeutics benefits from its specialization in the treatment of endocrine disorders, which represents a niche where the company has specific expertise and patents. This makes it difficult for new competitors to enter this market, protecting Corcept's existing market share.

Institutional Investor Share: 80% (estimated for 2025 based on historical trends)

Insider Buys/Sells: No significant changes in the last year (estimated for 2025)

Corcept Therapeutics Incorporated has traditionally had a high proportion of institutional investors, indicating the confidence of large investors in the company's long-term growth prospects. The estimated 80% share reflects this ongoing support.

Regarding insider buys and sells, there have been no significant changes in the last year. This could indicate that management has confidence in the current company strategy and valuation. Historically, insider transactions are an indicator of management's assessment of the company's future development.

Market share of Corcept Therapeutics: Estimated to be under 5% in the specialized pharmaceutical treatments sector (2025).

Main competitors and their market shares:

1. Pfizer Inc.: Approximately 10% (2025)
2. Johnson & Johnson: Approximately 9% (2025)
3. Merck & Co., Inc.: Approximately 8% (2025)
4. Bristol-Myers Squibb: Approximately 7% (2025)
5. AbbVie Inc.: Approximately 6% (2025)

Moat of Corcept Therapeutics: Corcept Therapeutics is known for its specialization in developing medications for the treatment of severe metabolic and psychiatric disorders, particularly through the use of glucocorticoid receptor antagonists. This provides the company with a certain moat through specialized research and development as well as patent protection.

However, compared to larger pharmaceutical companies like Pfizer or Johnson & Johnson, which have a broad product range and significant financial resources, Corcept's moat is less pronounced. The larger competitors often benefit from economies of scale, a global distribution infrastructure, and a diversified product portfolio, giving them a stronger and broader moat.

Corcept's advantage lies in its niche focus and expertise in a specific area, allowing the company to remain competitive in its specialized niche. Nevertheless, it remains vulnerable to the broader resources and innovation capabilities of larger pharmaceutical companies.

Revenue Growth: 10% (estimated 2024)
Research and Development Expenses: 20% of revenue (estimated 2024)
Net Income Growth: 8% (estimated 2024)

Corcept Therapeutics Incorporated has experienced solid revenue growth of around 10% in recent years, attributed to a successful product pipeline and a strong market position in the field of endocrinology. The company continues to invest significantly in research and development, accounting for approximately 20% of revenue. This indicates a strategic focus on securing future growth opportunities through innovative therapies.

The 8% net income growth in 2024 demonstrates the company's ability to increase profitability despite high investments in research and development. These metrics suggest that Corcept Therapeutics has a solid foundation for future growth.

Overall, Corcept Therapeutics' stock could present an attractive investment opportunity, especially for investors interested in long-term growth in the biotechnology sector. Ongoing investments in research and development could lead to new products and market share in the future.

Dividend: None (as of 2025)

Corcept Therapeutics Incorporated currently does not pay any dividends to its shareholders. The company has focused in the past on reinvesting its profits into research and development as well as into the growth of its business activities.

For investors seeking regular dividend payouts, Corcept may therefore be less attractive. Instead, the company could be interesting for investors who are looking for capital growth through stock price increases.